Our work on brain-based biomarkers of dementia in Down’s Syndrome has been selected for an oral presentation at the AD/PDTM 2017, the 13th​ International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders. In this work we show how amyloid burden in the brain as assessed with Positron Emission Tomography (PET) predicts future clinical transition to dementia.

Relationship between amyloid and increased risk of developing dementia in Down’s Syndrome.